Targeting Protein Aggregation in ALS.

Area of Science:

• Neuroscience
• Molecular Biology
• Biochemistry

Background:

• Proteinopathies are characterized by the abnormal accumulation of specific proteins within cells.
• Cellular proteostasis, the balance of protein synthesis, folding, and degradation, is crucial for health but can be disrupted by stress and aging.
• This disruption leads to widespread protein aggregation, a hallmark of many neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS).

Purpose of the Study:

• To review emerging drugs and therapeutic strategies for proteinopathies in the context of ALS.
• To highlight two main therapeutic approaches: targeting mutation-prone proteins and enhancing cellular protein homeostasis mechanisms.
• To discuss the broader implications of ALS research for neurodegenerative disease drug discovery.

Main Methods:

• Literature review of current clinical trials and research in ALS therapeutics.
• Analysis of therapeutic strategies focusing on protein aggregation and proteostasis.
• Synthesis of findings to provide insights into drug discovery for neurodegenerative diseases.

Main Results:

• Several therapeutic strategies targeting protein aggregation are currently in clinical trials for ALS.
• These strategies are broadly categorized into targeting specific aggregation-prone proteins and enhancing cellular protein homeostasis.
• Advances in ALS research are yielding valuable insights applicable to other neurodegenerative conditions.

Conclusions:

• Emerging therapies for ALS show promise for improving patient outcomes.
• Understanding and manipulating protein homeostasis is a key strategy in combating proteinopathies.
• ALS research contributes significantly to the broader field of neurodegenerative disease drug discovery.